Clinical features of patients with SCNSL in the entire cohort, patients with early-onset SCNSL vs late-onset SCNSL, and patients with isolated SCNSL vs concomitant systemic disease
| Variables . | All SCNSL . | Early SCNSL (≤6 months from EOT) . | Late SCNSL (>6 months from EOT) . | P value . | Isolated SCNSL . | Concomitant systemic disease . | P value . |
|---|---|---|---|---|---|---|---|
| No. of patients | 68 | 39 | 29 | 47 | 21 | ||
| Age, median (IQR), y | 71 (65-77) | 71.6 (60-76) | 70.7 (66-77) | .427 | 72.4 (65-77) | 68.3 (59-75) | .29 |
| CNS-IPI, n (%) | .008 | .26 | |||||
| 0-1 | 11 (16.2) | 2 (5.1) | 9 (31.0) | 10 (21.2) | 1 (4.7) | ||
| 2-3 | 20 (29.4) | 11 (28.2) | 9 (31.0) | 13 (27.6) | 7 (33.3) | ||
| 4-6 | 37 (54.4) | 26 (66.7) | 11 (38.0) | 24 (51.0) | 13 (62.0) | ||
| EN sites, n (%) | .04 | 2 (9.5) | .53 | ||||
| 0 | 6 (9) | 1 (2.6) | 5 (17.2) | 4 (8.5) | 5 | ||
| 1 | 24 (35) | 11 (28.2) | 13 (44.8) | 19 (40.4) | (23.9) | ||
| 2 | 17 (25) | 12 (30.8) | 5 (17.2) | 10 (21.3) | 7 (33.3) | ||
| >2 | 21 (31) | 15 (38.4) | 6 (20.6) | 14 (29.8) | 7 (33.3) | ||
| Testes, n (%) | .44 | 1 | |||||
| Yes | 8 (20) | 3 (11.5) | 5 (22.7) | 6 (17.6) | 2 (14.3) | ||
| No | 40 (80) | 23 (88.5) | 17 (77.3) | 28 (82.3) | 12 (85.7) | ||
| Treated with first-line R-CHOP–like therapy, n (%) | .5 | 1 | |||||
| Yes | 67 (98.5) | 38 (97.4) | 29 (100) | 46 (97.9) | 21 (100) | ||
| No | 1 (1.5) | 1 (2.6) | 0 (0) | 1 (2.1) | 0 (0) | ||
| Response to first-line treatment, n (%) | <.001 | .06 | |||||
| CR | 32 (47.1) | 10 (25.6) | 22 (75.9) | 26 (55.3) | 6 (28.6) | ||
| Non-CR | 36 (52.9) | 29 (74.4) | 7 (24.1) | 21 (44.7) | 15 (71.4) | ||
| HD-MTX CNS prophylaxis, n (%) | .32 | .61 | |||||
| Yes | 29 (42.6) | 19 (48.7) | 10 (34.5) | 19 (40.4) | 10 (47.6) | ||
| No | 39 (57.4) | 20 (51.3) | 19 (65.5) | 28 (59.6) | 11 (52.4) | ||
| EOT to SCNSL, n (%) | .06 | ||||||
| ≤6 months | 39 (57.3) | 23 (48.9) | 16 (76.2) | ||||
| >6 months | 29 (43.7) | 24 (51.1) | 5 (23.8) | ||||
| Type of SCNSL, n (%) | .06 | ||||||
| Isolated | 47 (69.1) | 23 (59.0) | 24 (82.8) | ||||
| Concomitant systemic disease | 21 (30.9) | 16 (41.0) | 5 (17.2) | ||||
| Detection of SCNSL, n (%) | .323 | .11 | |||||
| Neuroimaging∗ | 19 (27.9) | 8 (20.5) | 11 (37.9) | 13 (28.7) | 6 (28.5) | ||
| CSF examination | 26 (38.2) | 16 (41.0) | 10 (34.5) | 16 (34.0) | 10 (47.6) | ||
| Both | 23 (33.8) | 15 (38.5) | 8 (27.6) | 18 (38.3) | 5 (23.8) | ||
| Site of SCNSL, n (%) | .2 | .051 | |||||
| Parenchymal | 45 (66.2) | 23 (59) | 22 (75.9) | 35 (74.5) | 10 (47.6) | ||
| unifocal | 26 | 4 | 15 | 17 | 2 | ||
| multifocal | 19 | 19 | 7 | 18 | 8 | ||
| Nonparenchymal | 23 (33.8) | 16 (41) | 7 (24.1) | 12 (25.5) | 11 (52.4) | ||
| Time to death after SCNSL, median (IQR), mo | 3.2 (1-18) | 2.5 (1-7) | 7.1 (2-25) | .05 | 5.0 (1-27) | 2.4 (1-4) | .09 |
| Variables . | All SCNSL . | Early SCNSL (≤6 months from EOT) . | Late SCNSL (>6 months from EOT) . | P value . | Isolated SCNSL . | Concomitant systemic disease . | P value . |
|---|---|---|---|---|---|---|---|
| No. of patients | 68 | 39 | 29 | 47 | 21 | ||
| Age, median (IQR), y | 71 (65-77) | 71.6 (60-76) | 70.7 (66-77) | .427 | 72.4 (65-77) | 68.3 (59-75) | .29 |
| CNS-IPI, n (%) | .008 | .26 | |||||
| 0-1 | 11 (16.2) | 2 (5.1) | 9 (31.0) | 10 (21.2) | 1 (4.7) | ||
| 2-3 | 20 (29.4) | 11 (28.2) | 9 (31.0) | 13 (27.6) | 7 (33.3) | ||
| 4-6 | 37 (54.4) | 26 (66.7) | 11 (38.0) | 24 (51.0) | 13 (62.0) | ||
| EN sites, n (%) | .04 | 2 (9.5) | .53 | ||||
| 0 | 6 (9) | 1 (2.6) | 5 (17.2) | 4 (8.5) | 5 | ||
| 1 | 24 (35) | 11 (28.2) | 13 (44.8) | 19 (40.4) | (23.9) | ||
| 2 | 17 (25) | 12 (30.8) | 5 (17.2) | 10 (21.3) | 7 (33.3) | ||
| >2 | 21 (31) | 15 (38.4) | 6 (20.6) | 14 (29.8) | 7 (33.3) | ||
| Testes, n (%) | .44 | 1 | |||||
| Yes | 8 (20) | 3 (11.5) | 5 (22.7) | 6 (17.6) | 2 (14.3) | ||
| No | 40 (80) | 23 (88.5) | 17 (77.3) | 28 (82.3) | 12 (85.7) | ||
| Treated with first-line R-CHOP–like therapy, n (%) | .5 | 1 | |||||
| Yes | 67 (98.5) | 38 (97.4) | 29 (100) | 46 (97.9) | 21 (100) | ||
| No | 1 (1.5) | 1 (2.6) | 0 (0) | 1 (2.1) | 0 (0) | ||
| Response to first-line treatment, n (%) | <.001 | .06 | |||||
| CR | 32 (47.1) | 10 (25.6) | 22 (75.9) | 26 (55.3) | 6 (28.6) | ||
| Non-CR | 36 (52.9) | 29 (74.4) | 7 (24.1) | 21 (44.7) | 15 (71.4) | ||
| HD-MTX CNS prophylaxis, n (%) | .32 | .61 | |||||
| Yes | 29 (42.6) | 19 (48.7) | 10 (34.5) | 19 (40.4) | 10 (47.6) | ||
| No | 39 (57.4) | 20 (51.3) | 19 (65.5) | 28 (59.6) | 11 (52.4) | ||
| EOT to SCNSL, n (%) | .06 | ||||||
| ≤6 months | 39 (57.3) | 23 (48.9) | 16 (76.2) | ||||
| >6 months | 29 (43.7) | 24 (51.1) | 5 (23.8) | ||||
| Type of SCNSL, n (%) | .06 | ||||||
| Isolated | 47 (69.1) | 23 (59.0) | 24 (82.8) | ||||
| Concomitant systemic disease | 21 (30.9) | 16 (41.0) | 5 (17.2) | ||||
| Detection of SCNSL, n (%) | .323 | .11 | |||||
| Neuroimaging∗ | 19 (27.9) | 8 (20.5) | 11 (37.9) | 13 (28.7) | 6 (28.5) | ||
| CSF examination | 26 (38.2) | 16 (41.0) | 10 (34.5) | 16 (34.0) | 10 (47.6) | ||
| Both | 23 (33.8) | 15 (38.5) | 8 (27.6) | 18 (38.3) | 5 (23.8) | ||
| Site of SCNSL, n (%) | .2 | .051 | |||||
| Parenchymal | 45 (66.2) | 23 (59) | 22 (75.9) | 35 (74.5) | 10 (47.6) | ||
| unifocal | 26 | 4 | 15 | 17 | 2 | ||
| multifocal | 19 | 19 | 7 | 18 | 8 | ||
| Nonparenchymal | 23 (33.8) | 16 (41) | 7 (24.1) | 12 (25.5) | 11 (52.4) | ||
| Time to death after SCNSL, median (IQR), mo | 3.2 (1-18) | 2.5 (1-7) | 7.1 (2-25) | .05 | 5.0 (1-27) | 2.4 (1-4) | .09 |
Boldface values represent statistically significant results.
MRI of the brain and spinal cord.